|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5787 USD | -1.25% |
|
-22.32% | -34.49% |
| 01-29 | Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| 01-28 | Arch Biopartners Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -30.04 | -37.88 | -201.92 | -205.03 | -136.33 | |||||
Return on Total Capital | -127.43 | -101.86 | 656.48 | 208.54 | 54.14 | |||||
Return On Equity % | 30.18 | 33.71 | 66.67 | 79.54 | 37.74 | |||||
Return on Common Equity | 30.18 | 33.71 | 66.67 | 79.54 | 37.74 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -3.85 | -52.13 | -6.5 | -78.05 | 24.44 | |||||
SG&A Margin | 14.41 | 48.64 | 40.78 | 44.61 | 357.22 | |||||
EBITA Margin % | -21.08 | -103.36 | -145.99 | -162.86 | -411.11 | |||||
EBIT Margin % | -21.08 | -103.36 | -145.99 | -162.86 | -411.11 | |||||
Income From Continuing Operations Margin % | -30.1 | -145.94 | -167.71 | -184.76 | -562.7 | |||||
Net Income Margin % | -30.1 | -145.94 | -167.71 | -184.76 | -562.7 | |||||
Net Avail. For Common Margin % | -30.1 | -145.94 | -167.71 | -184.76 | -562.7 | |||||
Normalized Net Income Margin | -18.81 | -91.21 | -104.82 | -115.47 | -351.69 | |||||
Levered Free Cash Flow Margin | -65.3 | 62.8 | 34.51 | -61.01 | -431.64 | |||||
Unlevered Free Cash Flow Margin | -60.9 | 82.84 | 45.81 | -49.54 | -373.17 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 2.28 | 0.59 | 2.21 | 2.01 | 0.53 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.84 | 0.22 | 0.2 | 0.18 | 0.03 | |||||
Quick Ratio | 0.83 | 0.21 | 0.19 | 0.17 | 0.02 | |||||
Operating Cash Flow to Current Liabilities | -0.93 | 0.17 | -0.04 | -0.44 | -0.4 | |||||
Average Days Payable Outstanding | 86.41 | 180.5 | 76.27 | 133.01 | 2.94K | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -133.01 | -98.71 | -91.04 | -63.71 | -73.16 | |||||
Total Debt / Total Capital | 402.97 | -7.64K | -1.02K | -175.58 | -272.64 | |||||
LT Debt/Equity | -86.59 | -51.73 | -12.78 | - | - | |||||
Long-Term Debt / Total Capital | 262.33 | -4K | -142.6 | - | - | |||||
Total Liabilities / Total Assets | 245.5 | 819.16 | 570.45 | 564.69 | 3.81K | |||||
EBIT / Interest Expense | -3 | -3.22 | -8.07 | -8.87 | -4.39 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 5.63K | -75.18 | 105.63 | 6.97 | -87 | |||||
Gross Profit, 1 Yr. Growth % | -92.94 | 235.72 | -74.35 | 1.18K | -104.07 | |||||
EBITA, 1 Yr. Growth % | -81.29 | 21.69 | 190.44 | 19.32 | -67.17 | |||||
EBIT, 1 Yr. Growth % | -81.29 | 21.69 | 190.44 | 19.32 | -67.17 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -74.73 | 20.36 | 136.3 | 17.84 | -60.39 | |||||
Net Income, 1 Yr. Growth % | -74.73 | 20.36 | 136.3 | 17.84 | -60.39 | |||||
Normalized Net Income, 1 Yr. Growth % | -74.73 | 20.36 | 136.3 | 17.84 | -60.39 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -75.31 | 18.74 | 135.14 | 16.14 | -61.74 | |||||
Total Assets, 1 Yr. Growth % | 259.94 | -76.7 | 88.4 | -20.11 | -88.83 | |||||
Tangible Book Value, 1 Yr. Growth % | 0.37 | 15.15 | 23.25 | -21.09 | -10.72 | |||||
Common Equity, 1 Yr. Growth % | 0.37 | 15.15 | 23.25 | -21.09 | -10.72 | |||||
Cash From Operations, 1 Yr. Growth % | 56.49 | -116.09 | -148.82 | 895.91 | -32.05 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 1.71K | -123.87 | 12.98 | -289.14 | -8 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 7.77K | -133.76 | 13.72 | -215.68 | -2.05 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 543.44 | 276.97 | -28.56 | 48.31 | -62.7 | |||||
Gross Profit, 2 Yr. CAGR % | -67.33 | -51.33 | -7.2 | 81.48 | -27.69 | |||||
EBITA, 2 Yr. CAGR % | -34.57 | -52.28 | 88 | 86.16 | -37.41 | |||||
EBIT, 2 Yr. CAGR % | -34.57 | -52.28 | 88 | 86.16 | -37.41 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -25.24 | -44.85 | 68.64 | 66.87 | -31.68 | |||||
Net Income, 2 Yr. CAGR % | -25.24 | -44.85 | 68.64 | 66.87 | -31.68 | |||||
Normalized Net Income, 2 Yr. CAGR % | -25.24 | -44.85 | 68.64 | 66.87 | -31.68 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -26.89 | -45.85 | 67.09 | 65.26 | -33.34 | |||||
Accounts Receivable, 2 Yr. CAGR % | 646.45 | - | - | - | - | |||||
Total Assets, 2 Yr. CAGR % | 78.98 | -8.43 | -33.75 | 22.68 | -70.12 | |||||
Tangible Book Value, 2 Yr. CAGR % | 21.34 | 7.51 | 19.13 | -1.38 | -16.07 | |||||
Common Equity, 2 Yr. CAGR % | 21.34 | 7.51 | 19.13 | -1.38 | -16.07 | |||||
Cash From Operations, 2 Yr. CAGR % | 28.52 | -49.83 | -71.98 | 120.5 | 160.14 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 59.51 | 107.78 | -48.07 | 46.18 | 31.92 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 59.67 | 415.56 | -38.04 | 14.69 | 6.45 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | - | 117.41 | 208.01 | -18.27 | -34.11 | |||||
Gross Profit, 3 Yr. CAGR % | -53.63 | -28.97 | -60.68 | 122.78 | -48.81 | |||||
EBITA, 3 Yr. CAGR % | -34.65 | -19.54 | -12.87 | 61.56 | 4.4 | |||||
EBIT, 3 Yr. CAGR % | -34.65 | -19.54 | -12.87 | 61.56 | 4.4 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -27.07 | -12.38 | -10.42 | 49.65 | 3.32 | |||||
Net Income, 3 Yr. CAGR % | -27.07 | -12.38 | -10.42 | 49.65 | 3.32 | |||||
Normalized Net Income, 3 Yr. CAGR % | -27.07 | -12.38 | -10.42 | 49.65 | 3.32 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -28.82 | -14.06 | -11.66 | 48.02 | 1.48 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | - | - | -26.86 | - | |||||
Total Assets, 3 Yr. CAGR % | 46.13 | -9.29 | 16.47 | -29.48 | -44.8 | |||||
Tangible Book Value, 3 Yr. CAGR % | 65.06 | 19.24 | 12.52 | 3.85 | -4.6 | |||||
Common Equity, 3 Yr. CAGR % | 65.06 | 19.24 | 12.52 | 3.85 | -4.6 | |||||
Cash From Operations, 3 Yr. CAGR % | 11.47 | -35.71 | -50.28 | -7.87 | 48.94 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 34.97 | -15.31 | 69.59 | -20.1 | 25.28 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 33.62 | -4.88 | 211.5 | -23.7 | 8.82 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 86.57 | 32.38 | |||||
Gross Profit, 5 Yr. CAGR % | -18.31 | -3.81 | -38.8 | 3.37 | -49.83 | |||||
EBITA, 5 Yr. CAGR % | -3.41 | -11.73 | -0.28 | 12.54 | -23.67 | |||||
EBIT, 5 Yr. CAGR % | -3.41 | -11.73 | -0.28 | 12.54 | -23.67 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 2.75 | -5.86 | 1.98 | 13.38 | -19.62 | |||||
Net Income, 5 Yr. CAGR % | 2.75 | -5.86 | 1.98 | 13.38 | -19.62 | |||||
Normalized Net Income, 5 Yr. CAGR % | 2.75 | -5.86 | 1.98 | 13.38 | -19.62 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -0.06 | -8.31 | 0.14 | 11.63 | -21.07 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 85.23 | - | |||||
Total Assets, 5 Yr. CAGR % | 63.69 | 55.7 | 6.49 | 2.35 | -32.42 | |||||
Tangible Book Value, 5 Yr. CAGR % | 69.24 | 51.32 | 44.87 | 10.52 | 0.07 | |||||
Common Equity, 5 Yr. CAGR % | 69.24 | 51.32 | 44.87 | 10.52 | 0.07 | |||||
Cash From Operations, 5 Yr. CAGR % | 32.48 | -8.8 | -35.83 | 5.25 | -3.62 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 49.25 | 63.46 | -7.89 | 5.35 | 53.38 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 48.29 | 83.1 | -1.74 | 2.51 | 102.74 |
- Stock Market
- Equities
- ACHFF Stock
- Financials Arch Biopartners Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















